Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Researchers examine new genes to control mosquito-borne diseases

An Iowa State University researcher searched for new genes that are turned on during infection in a type of mosquito that is not only a pest, but transmits disease-causing pathogens.

4 Oct 2010

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

Tamir Biotechnology, Inc. announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) reported test results confirming two of our lead compounds outperformed market leader Roche's drug Ganciclovir in cell culture and plaque reduction assay (the gold standard) for Cytomegalovirus (CMV) disease. Additionally, antiviral activity was also apparent against other human herpesviruses, namely, HSV-1 (cold sores), HSV-2 (genital herpes), and Varicella-Zoster Virus (VZV) (chicken-pox and shingles).

29 Sep 2010

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.

24 Sep 2010

Dengue fever vaccine in the pipeline

Australians researchers are moving towards producing the first ever vaccine for dengue fever, the potentially life-threatening infection spread by mosquitoes in the tropics. At present late stage clinical trials are underway for a vaccine that would protect against all four known strains of the disease. Participants are now being recruited in Perth, Adelaide and Brisbane.

20 Sep 2010

395 new vaccines being developed for infectious diseases: PhRMA

Critical challenges remain in the centuries-old battles against infectious diseases, particularly as bacteria and viruses mutate and as the threat of bioterrorism grows. Responding to this need, America's biopharmaceutical research companies this year have 395 new medicines and vaccines in the pipeline to fight infectious diseases. All 395 are in later stages of development, meaning in clinical trials or under Food and Drug Administration (FDA) review.

10 Sep 2010

Global warming may eliminate plague

While many climate experts and environmentalists explore the negative effects of global warming, a new study reveals a positive outcome of the warming of the planet: the potential elimination of the plague. Global warming affects temperatures and precipitation regimes that play a pivotal role in the lives of rodents and fleas; rodents and fleas are responsible for maintenance and spread of plague to human populations. Plague can be fatal if the symptoms are not recognized and treated within 24 hours.

8 Sep 2010

Media examine floods' impact in Pakistan

News outlets reported on the effects of major flooding in Pakistan and described the situation on the ground.

2 Sep 2010

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

Malaysia is still "considering releasing" up to 3,000 mosquitoes that are genetically modified to "combat dengue fever, in a landmark field trial that has come in for criticism from environmentalists," Agence France-Presse reports. The insects are modified "so that their offspring quickly die," which researchers hope will cull the population and lessen the risk of dengue.

30 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

"New bipartisan legislation was introduced in the U.S. Senate last week which seeks to encourage innovative [research and development] R&D by drugmakers aimed at treating rare and neglected pediatric diseases," PharmaTimes reports.

11 Aug 2010

NIAID launches clinical trials of dengue vaccine

After more than a decade of development, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials to test a vaccine to protect against the dengue virus, a product researchers hope may one day "help prevent a disease to which 2.5 billion people are exposed," CIDRAP News reports (Roos, 8/9).

11 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Need for shelter in Haiti; Avoiding disease outbreaks; Presidential election

USAID Director Rajiv Shah "says shelter and rubble removal are immediate priorities in the reconstruction efforts in earthquake-devastated Haiti," VOA News reports. Shah briefed the House Foreign Relations Subcommittee on the Western Hemisphere Thursday, and also "said between 300,000 and 400,000 units of shelter are needed. He said aid workers are trying to provide about 135,000 transitional structures right now."

31 Jul 2010

Dengue fever emerges as major health threat in Gulf coast cities

Several cases of dengue fever, a potentially fatal viral disease transmitted by the bite of urban dwelling Aedes aegypti and Aedes albopictus mosquitoes, have recently been reported in the continental United States. Prevalent in Central America and the Caribbean, dengue fever's most common symptoms include fever, chills, headache, and body aches lasting several days. The disease's more threatening form, dengue hemorrhagic fever, can cause internal bleeding, loss of blood pressure, and death. Over the past five years, outbreaks of both forms of the disease have been reported in Texas and Florida.

28 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

IBM today announced plans to enlist some of the company's leading scientists and technologists to help medical practitioners and insurance companies provide high-quality, evidence-based care to patients. As part of this initiative, IBM is collaborating with clinicians in medical institutions and hiring medical doctors to work alongside its researchers to develop new technologies, scientific advancements and business processes for healthcare and insurance providers.

15 Jul 2010

IBM and Peking University People's Hospital build evidence-based patient centric care system

IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.

15 Jul 2010

Bacteria that will kill Dengue bearing mosquitoes on the way

Dengue is a deadly viral fever spread by mosquito bites that kills thousands around the world each year. Now researchers from James Cook University and University of Queensland are working on a bacterium called Wolbachia that can stop the spread of this virus.

6 Jul 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Scientists have devised a way to automate and accelerate a manual, complex process that enables researchers to more easily discover the structure of cancer-related proteins, and, eventually, formulate cancer cures. This new, automated approach may also help the exploration of other diseases and food-related research.

15 Jun 2010

Dengue Fever News and Research

Further Reading

Researchers examine new genes to control mosquito-borne diseases

Tamir's compounds perform better than Ganciclovir for Cytomegalovirus disease: Study

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Dengue fever vaccine in the pipeline

395 new vaccines being developed for infectious diseases: PhRMA

Global warming may eliminate plague

Media examine floods' impact in Pakistan

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

Tamir Biotechnology's three compounds effective show potential for yellow fever

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

NIAID launches clinical trials of dengue vaccine

NIH begins human clinical testing for dengue virus vaccine

Need for shelter in Haiti; Avoiding disease outbreaks; Presidential election

Dengue fever emerges as major health threat in Gulf coast cities

NIH awards MacroGenics $9.8 million grant for three projects

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

IBM and Peking University People's Hospital build evidence-based patient centric care system

Bacteria that will kill Dengue bearing mosquitoes on the way

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News